Phase II study with pharmacodynamic evaluation of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC)

被引：0
|
作者：
Fontana, A. [1 ]
Galli, L. [2 ]
Derosa, L. [2 ]
Minuti, G. [2 ]
D'Arcangelo, M. [2 ]
Bursi, S. [2 ]
Landi, L. [2 ]
Bocci, G. [3 ]
Santini, D. [4 ]
Falcone, A. [3 ]
机构：
[1] Azienda Osped Univ Pisana, Pisa, Italy
[2] ASL6 Livorno, Med Oncol, Livorno, Italy
[3] Univ Pisa, Pisa, Italy
[4] Univ Campus Biomed, Rome, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71414-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：417 / 417
页数：1
相关论文
共 50 条
  • [1] DOCETAXEL-PREDNISONE (DP) PLUS METRONOMIC CYCLOPHOSPHAMIDE (CTX) AND CELECOXIB (C) AS FIRST LINE TREATMENT IN CASTRATION RESISTANT PROSTATE CANCER (CRPC): PHASE II TRIAL WITH PHARMACODYNAMIC EVALUATION
    Fontana, A.
    Galli, L.
    Derosa, L.
    Minuti, G.
    D'Arcangelo, M.
    Fontana, E.
    Di Marsico, R.
    Venditti, O.
    Galluzzo, S.
    Landi, L.
    Bursi, S.
    Galli, C.
    Bona, E.
    Bocci, G.
    Antonuzzo, A.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20
  • [2] Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first-line treatment in castration resistant prostate cancer (CRPC) patients (Pts)
    Fontana, A.
    Bocci, G.
    Galli, L.
    Derosa, L.
    Minuti, G.
    D'Arcangelo, M.
    Santini, D.
    Landi, L.
    Bursi, S.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] DOCETAXEL (D) PLUS PREDNISONE (P) IN COMBINATION WITH METRONOMIC CYCLOPHOSPHAMIDE (CTX) AND CELECOXIB (C) AS FIRST LINE TREATMENT IN METASTATIC HORMONE REFRACTORY PROSTATE CANCER (MHRPC): A PHASE II CLINICAL TRIAL WITH PHARMACODYNAMIC EVALUATION
    Fontana, A.
    Bocci, G.
    D'Arcangelo, M.
    Galli, L.
    Bursi, S.
    Landi, L.
    Battaglini, P.
    Caponi, S.
    Del Tacca, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 198 - 199
  • [4] Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II clinical trial with pharmacodynamic evaluation
    Fontana, A.
    Bocci, G.
    D'Arcangelo, M.
    Galli, L.
    Galli, C.
    Bursi, S.
    Landi, L.
    Antonuzzo, A.
    Del Tacca, M.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Results of a phase II study of picoplatin with docetaxel and prednisone in first-line treatment of castration-resistant prostate cancer (CRPC)
    De Jager, R. L.
    Roman, L.
    Lopatkin, N.
    Karlov, P.
    Breitz, H.
    Earhart, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer
    Cardillo, Irene
    Spugnini, Enrico P.
    Galluzzo, Paola
    Contestabile, Michela
    Dell'Anna, Maria Lucia
    Picardo, Mauro
    Crispi, Stefania
    Calogero, Raffaele A.
    Piccolo, Maria Teresa
    Arigoni, Maddalena
    Cantarella, Daniela
    Boccellino, Mariarosaria
    Quagliuolo, Lucio
    Ferretti, Gianluigi
    Carlini, Paolo
    Felici, Alessandra
    Boccardo, Francesco
    Cognetti, Francesco
    Baldi, Alfonso
    FUTURE ONCOLOGY, 2013, 9 (09) : 1375 - 1388
  • [7] Docetaxel Plus Oral Metronomic Cyclophosphamide: A Phase II Study With Pharmacodynamic and Pharmacogenetic Analyses in Castration-Resistant Prostate Cancer Patients
    Derosa, Lisa
    Galli, Luca
    Orlandi, Paola
    Fioravanti, Anna
    Di Desidero, Teresa
    Fontana, Andrea
    Antonuzzo, Andrea
    Biasco, Elisa
    Farnesi, Azzurra
    Marconcini, Riccardo
    Francia, Giulio
    Danesi, Romano
    Falcone, Alfredo
    Bocci, Guido
    CANCER, 2014, 120 (24) : 3923 - 3931
  • [8] Phase I trial of metronomic cyclophosphamide (CTX) and lenalidomide (LEN) in patients with castration-resistant prostate cancer (CRPC).
    Wang, Jue
    McGuire, Timothy R.
    Schwarz, James K.
    Meza, Jane L.
    Talmadge, James E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [9] Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for patients (pts) with castration-resistant prostate cancer (CRPC).
    Medioni, J.
    Ferrero, J.
    Deplanque, G.
    Maurina, T.
    Rodier, J. P.
    Raymond, E.
    Allyon, J.
    Renaux, S.
    Dufour-Lamartinie, J.
    Oudard, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for castration-resistant prostate cancer (CRPC) patients (pts)
    Medioni, J.
    Deplanque, G.
    Ferrero, J.
    Maurina, T.
    Rodier, J. P.
    Raymond, E.
    Allyon, J.
    Renaux, S.
    Dufour-Lamartinie, J.
    Oudard, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
12345